Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.

Cancer Med · 2024 · PMC11157197 · PMID 38847087

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

approaching significancep = 0.053so close (0.05 < p ≤ 0.1)

IrAEs were associated with a significantly higher OS (hazard ratio [HR] 0.319; 95% CI 0.113–0.906; p = 0.032) as well as a higher PFS, approaching significance (HR 0.428; 95% CI 0.181–1.012; p = 0.053).

also in 412 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.